Navigation Links
Combined mammography and breast MRI useful for some high-risk women
Date:2/22/2010

OAK BROOK, Ill. Annual breast cancer screening with both mammography and magnetic resonance imaging (MRI) is likely to be a cost-effective way to improve life expectancy in women with an increased risk of breast cancer, according to a new study published in the March issue of Radiology. The findings support current American Cancer Society screening recommendations.

"For women at the highest risk of breast cancer, using both breast MRI and mammography together for screening will likely reduce their chances of dying from breast cancer and help them live longer, healthier lives," said the study's lead author, Janie M. Lee, M.D., radiologist from Massachusetts General Hospital in Boston.

Women with certain mutations in the BRCA1 gene have a significantly increased lifetime risk of developing breast cancer. Mammography, the current standard for breast cancer screening in the general population, detects fewer than half of breast cancers in these high-risk women, in part because their younger age at screening and associated increased breast density make visualizing tumors challenging.

While breast MRI is a useful adjunct to mammography for screening women at increased genetic risk of breast cancer, it is more time consuming and expensive than mammography and has a higher incidence of false-positive findings.

For the study, Dr. Lee and colleagues compared the costs and benefits of film mammography, of MRI and of combined mammography and MRI in a hypothetical group of 25-year-old women with BRCA1 mutations.

The researchers used statistical modeling to estimate the number of quality adjusted life years (QALYs) gained by screening, along with lifetime costs. QALYs are a measure of both the quantity and quality of life.

Women undergoing annual combined screening with both mammography and MRI gained 49.62 QALYs at a cost of $110,973. Annual MRI screening alone provided 49.50 QALYs at a cost of $108,641, while annual mammography alone provided 44.46 QALYs at a cost of $100,336.

Adding annual MRI to annual mammography screening cost $69,125 for each additional QALY gained. Although there is no consensus in the U.S. on what constitutes a cost-effective intervention, commonly cited threshold values range from $50,000 to $100,000 per QALY, according to Dr. Lee.

Annual combined screening was best at detecting early stage cancers and provided the greatest relative mortality reduction. Combined screening became more cost-effective as breast cancer risk increased, and less cost-effective as risk decreased.

MRI screening was associated with an increase in false-positive results. Annual mammography resulted in 37 false-positive screening examinations for every breast cancer death averted. The addition of annual MRI increased the number of false-positive results to 137 for each breast cancer death averted.

"The benefits provided by MRI are balanced by an increased chance of needing additional tests to evaluate a possible abnormality, and perhaps even a biopsy that might in the end show no cancer," Dr. Lee said.


'/>"/>

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America
Source:Eurekalert

Related medicine news :

1. Study Finds New Version of QIAGENs HPV Test for Developing Countries Could Reduce Risk of Cervical Cancer by More than Half When Combined With Appropriate Treatment
2. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
3. Combined Boards Provide Better Care to More Clients More Efficiently
4. Combined HRT increases risk of lobular breast cancer fourfold after just 3 years of use
5. Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors
6. AT4 wireless and Ekahau Partner to Deploy Combined Asset and Staff Tracking Solution for Hospitals
7. Combined stenting and photodynamic therapy improves survival in late stage liver cancer patients
8. USC researchers find benefit for lymphoma patients in combined PET-CT scanning
9. Home Oxygen Leaders Warn That Competitive Bidding Program Reductions Combined with Other Pending and Proposed Cuts Are Unsustainable and Unpredictable
10. Combined physical and genetic map finds cancers ignition key
11. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has issued an important reminder to employers to prevent ... Employers with workers exposed to high temperatures should establish a complete heat illness ...
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: